Patrick J. Heron
CIK: 0001365617
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (38 total)
- Jun 15, 2026MIRM
Mirum Pharmaceuticals, Inc.
Award(A)DirectDeferred Stock Units
2K shares- - Jun 15, 2026MIRM
Mirum Pharmaceuticals, Inc.
Award(A)DirectStock Option (right to buy)
3.8K shares- - Jun 5, 2026ARQT
Arcutis Biotherapeutics, Inc.
Award(A)Direct5.8K shares- - Jun 4, 2026MBX
MBX Biosciences, Inc.
Award(A)DirectStock option (right to buy)
12.5K shares- - Jan 23, 2026MIRM
Mirum Pharmaceuticals, Inc.
Other(J)Indirect159.3K shares- - Jan 23, 2026MIRM
Mirum Pharmaceuticals, Inc.
Purchase(P)Indirect131.4K shares at avg. $68.48$9.0M - Sep 26, 2025MBX
MBX Biosciences, Inc.
Purchase(P)Indirect666.7K shares at avg. $18.00$12.0M - Jun 23, 2025HLVX
HilleVax, Inc.
Award(A)Direct17.2K shares- - Jun 13, 2025ARQT
Arcutis Biotherapeutics, Inc.
Purchase(P)Indirect2.6K shares at avg. $13.08$35K - Jun 12, 2025ARQT
Arcutis Biotherapeutics, Inc.
Award(A)Direct7.6K shares- - Jun 5, 2025ARQT
Arcutis Biotherapeutics, Inc.
Purchase(P)Indirect378 shares at avg. $13.41$5K - Jun 5, 2025MBX
MBX Biosciences, Inc.
Award(A)DirectStock option (right to buy)
16K shares- - Jun 4, 2025ARQT
Arcutis Biotherapeutics, Inc.
Purchase(P)Indirect1.9K shares at avg. $13.32$25K - May 29, 2025MIRM
Mirum Pharmaceuticals, Inc.
Award(A)DirectDeferred Stock Units
4K shares- - May 29, 2025MIRM
Mirum Pharmaceuticals, Inc.
Exercise(M)Direct5.7K shares- - May 29, 2025MIRM
Mirum Pharmaceuticals, Inc.
Award(A)DirectStock Option (right to buy)
6.3K shares- - May 22, 2025ARQT
Arcutis Biotherapeutics, Inc.
Purchase(P)Indirect2.5K shares at avg. $13.65$34K - May 21, 2025ARQT
Arcutis Biotherapeutics, Inc.
Purchase(P)Indirect2.5K shares at avg. $13.66$34K - May 15, 2025ARQT
Arcutis Biotherapeutics, Inc.
Purchase(P)Indirect2.5K shares at avg. $13.62$34K - May 14, 2025ARQT
Arcutis Biotherapeutics, Inc.
Purchase(P)Indirect6.3K shares at avg. $13.76$87K - May 13, 2025ARQT
Arcutis Biotherapeutics, Inc.
Purchase(P)Indirect2.4K shares at avg. $13.76$33K - May 9, 2025ARQT
Arcutis Biotherapeutics, Inc.
Purchase(P)Indirect6.3K shares at avg. $13.60$86K - Mar 17, 2025MIRM
Mirum Pharmaceuticals, Inc.
Purchase(P)Indirect21 shares at avg. $43.93$922.61 - Mar 14, 2025MIRM
Mirum Pharmaceuticals, Inc.
Purchase(P)Indirect528 shares at avg. $44.11$23K - Mar 11, 2025MIRM
Mirum Pharmaceuticals, Inc.
Purchase(P)Indirect963 shares at avg. $43.77$42K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 15, 2026 |  MIRM Mirum Pharmaceuticals, Inc. | Award(A) Deferred Stock Units | 1,980 | - | - | Direct |
| Jun 15, 2026 | MIRM Mirum Pharmaceuticals, Inc. | Award(A) Stock Option (right to buy) | 3,772 | - | - | Direct |
| Jun 5, 2026 |  ARQT Arcutis Biotherapeutics, Inc. | Award(A) | 5,778 | - | $0 | Direct |
| Jun 4, 2026 |  MBX MBX Biosciences, Inc. | Award(A) Stock option (right to buy) | 12,500 | - | - | Direct |
| Jan 23, 2026 | MIRM Mirum Pharmaceuticals, Inc. | Other(J) | 159,277 | - | $0 | Indirect |
| Jan 23, 2026 | MIRM Mirum Pharmaceuticals, Inc. | Purchase(P) | 131,425 | $68.48 | $8,999,984 | Indirect |
| Sep 26, 2025 | MBX MBX Biosciences, Inc. | Purchase(P) | 666,666 | $18.00 | $11,999,988 | Indirect |
| Jun 23, 2025 |  HLVX HilleVax, Inc. | Award(A) | 17,199 | - | - | Direct |
| Jun 13, 2025 | ARQT Arcutis Biotherapeutics, Inc. | Purchase(P) | 2,646 | $13.08 | $34,610 | Indirect |
| Jun 12, 2025 | ARQT Arcutis Biotherapeutics, Inc. | Award(A) | 7,609 | - | - | Direct |
| Jun 5, 2025 | ARQT Arcutis Biotherapeutics, Inc. | Purchase(P) | 378 | $13.41 | $5,069 | Indirect |
| Jun 5, 2025 | MBX MBX Biosciences, Inc. | Award(A) Stock option (right to buy) | 16,000 | - | - | Direct |
| Jun 4, 2025 | ARQT Arcutis Biotherapeutics, Inc. | Purchase(P) | 1,890 | $13.32 | $25,177 | Indirect |
| May 29, 2025 | MIRM Mirum Pharmaceuticals, Inc. | Award(A) Deferred Stock Units | 3,977 | - | - | Direct |
| May 29, 2025 | MIRM Mirum Pharmaceuticals, Inc. | Exercise(M) | 5,703 | - | - | Direct |
| May 29, 2025 | MIRM Mirum Pharmaceuticals, Inc. | Award(A) Stock Option (right to buy) | 6,268 | - | - | Direct |
| May 22, 2025 | ARQT Arcutis Biotherapeutics, Inc. | Purchase(P) | 2,520 | $13.65 | $34,398 | Indirect |
| May 21, 2025 | ARQT Arcutis Biotherapeutics, Inc. | Purchase(P) | 2,520 | $13.66 | $34,423 | Indirect |
| May 15, 2025 | ARQT Arcutis Biotherapeutics, Inc. | Purchase(P) | 2,520 | $13.62 | $34,317 | Indirect |
| May 14, 2025 | ARQT Arcutis Biotherapeutics, Inc. | Purchase(P) | 6,300 | $13.76 | $86,691 | Indirect |
| May 13, 2025 | ARQT Arcutis Biotherapeutics, Inc. | Purchase(P) | 2,374 | $13.76 | $32,661 | Indirect |
| May 9, 2025 | ARQT Arcutis Biotherapeutics, Inc. | Purchase(P) | 6,300 | $13.60 | $85,691 | Indirect |
| Mar 17, 2025 | MIRM Mirum Pharmaceuticals, Inc. | Purchase(P) | 21 | $43.93 | $923 | Indirect |
| Mar 14, 2025 | MIRM Mirum Pharmaceuticals, Inc. | Purchase(P) | 528 | $44.11 | $23,291 | Indirect |
| Mar 11, 2025 | MIRM Mirum Pharmaceuticals, Inc. | Purchase(P) | 963 | $43.77 | $42,155 | Indirect |
1-25 of 38 transactions
About Heron Patrick J
Heron Patrick J (SEC CIK 0001365617) files insider reports with the SEC as Director of Mirum Pharmaceuticals, Inc. (MIRM), Director of Arcutis Biotherapeutics, Inc. (ARQT) and Director of MBX Biosciences, Inc. (MBX). Signal8 also holds filings tied to 1 other company.
Signal8 holds 26 ownership filings by Heron Patrick J (1 Form 3, 25 Form 4), filed between Sep 10, 2024 and Jun 17, 2026. Those filings report 38 transactions, from Jun 6, 2024 to Jun 15, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Heron Patrick J's filings is in CARMEL, IN.
Recent filings by Heron Patrick J
- Jun 15, 2026: Grants or awards of MIRM derivative securities (2 lines, Form 4, code A).
- Jun 5, 2026: Grant or award of ARQT shares (Form 4, code A).
- Jun 4, 2026: Grant or award of MBX derivative securities (Form 4, code A).
- Jan 23, 2026: Other transaction of MIRM shares (Form 4, code J).
- Jan 23, 2026: Open-market purchase of MIRM shares (Form 4, code P).
Other insiders filing for Mirum Pharmaceuticals, Inc. (MIRM)
- Howe Jolanda, SVP, GLOBAL CONTROLLER
- Myers Robert Paul, Chief Medical Officer
- Peetz Christopher, CHIEF EXECUTIVE OFFICER
- BJERKHOLT ERIC, CHIEF FINANCIAL OFFICER
- Walbert Timothy P, Director
- Cardon Lon, Director